Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe

Infectious Agents and Cancer

Volumn 4, Issue 1, 2009, Pages

  Chin'ombe, Nyasha ^a,b   Chavhunduka, Evans ^b,c   Matarira, Hilda T ^b,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b University of Zimbabwe   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d GREAT ZIMBABWE UNIVERSITY   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SEROPREVALENCE; ZIMBABWE;

EID: 70350338226     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-4-15     Document Type: Article

References (39)

1. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. E Chokunonga LM Levy MT Bassett BG Mauchaza DB Thomas DM Parkin, Int J Cancer 2000 85 54 59 10.1002/(SICI)1097- 0215(20000101)85:1<54::AID-IJC103.0.CO;2-D 10585583
2. Cancer in Indigenous Africans - burden, distribution, and trends. DM Parkin F Sitas M Chirenje L Stein R Abratt H Wabinga, Lancet Oncol 2008 9 683 692 10.1016/S1470-2045(08)70175-X 18598933
3. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. CJ Chen HI Yang J Su CL Jen SL You SN Lu GT Huang UH Iloeje, JAMA 2006 295 65 73 10.1001/jama.295.1. 65 16391218
4. Chronic hepatitis B. AS Lok, N Engl J Med 2000 346 1682 1683 10.1056/NEJM200205303462202
5. World Health Organization, Hepatitis B 2000 Factsheet no. 204 10.1016/S1386-6532(05)00384-7
6. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. D Lavanchy, J Clin Virol 2005 34 S1 1 3 10.1016/j.jhep.2007.11.011 16461208
7. Natural history of chronic hepatitis B. G Fattovich F Bortolotti F Donato, J Hepatol 2008 48 335 352 18096267
8. Chronic Hepatitis B virus infection: Treatment strategies for the next millenium. AH Malik WM Lee, Ann Intern Med 2000 132 723 731 10787366
9. Using natural history to guide management of chronic hepatitis B. D Ratinam W Siervert, Modern Medicine of South Africa 2009 8 11 24 35 10.1002/hep.1840360706
10. Natural history of chronic hepatitis C. LB Seeff, Hepatol 2002 36 35 S46 10.1016/S1473-3099(05)70216-4
11. Global epidemiology of hepatitis C virus infection. CW Shepard L Finelli MJ Alter, Lancet Infect Dis 2005 5 558 567 10.1056/NEJM200107053450107 16122679
12. Hepatitis C virus infection. GM Lauer BD Walker, N Engl J Med 2001 345 41 52 10.1002/hep.510260711 11439948
13. Epidemiology of Hepatitis C. MJ Alter, Hepatol 1997 26 62S 65S 10.1046/j.1365-2893.1998.0050s1009.x
14. The natural course of chronic hepatitis C: implications for clinical practice. GM Dusheiko, J Viral Hepat 1998 5 S1 9 12 10.1016/S0168-8278(98)80339- 5 9795923
15. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. K Ikeda S Saitoh Y Suzuki M Kobayashi A Tsubota I Koida Y Arase M Fukuda K Chayama N Murashima H Kumada, J Hepatol 1998 28 930 938 10.1002/jmv.1025 9672166
16. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 Allele. N Akuta K Chayama F Suzuki T Someya M Kobayashi A Tsubota Y Suzuki S Saitoh Y Arase K Ikeda H Kumada, J Med Virol 2001 64 109 116 10.1053/j.gastro.2004.09.014 11360242
17. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. G Fattovich T Stroffolini I Zagni F Donato, Gastroenterol 2004 127 S1 35 50
18. National Institutes of Health, Management of Hepatitis C National Institutes of Health Consensus Development Conference Panel Statement On-Line 1997
19. Secret killers: hepatitis C virus infection in perspective. C Lopez, Health in the Commonwealth, Challenges and Solutions Kensington Publ. Ltd 1999
20. Hepatitis C virus infection in chronic liver disease in Natal. PN Soni DR Tait W Gopaul MA Sthar AE Simjee, S Afri Med J 1996 86 80 83 10.1016/0140-6736(92)92234-7
21. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. A Alberti G Morsica L Chemello D Cavalletto F Noventa P Pontisso A Ruol, Lancet 1992 340 697 698 1355801
22. Hepatitis C virus in Zimbabwe. IT Gangaidzo VM Moyo H Khumalo T Saungweme ZAR Gomo T Ronalt VR Gordeuk, Cent Afr J Med 1997 43 122 125 10.1016/S0035-9203(97)90387-4 9505450
23. Hepatitis B and C virus and hepatocellular carcinoma. IO Olubuyide B Aliyu OA Olalelye SO Ola F Olawuyi UH Malabu SO Odemuyiwa GN Odaibo GC Cook, Trans R Soc Trop Med Hyg 1997 91 38 41 10.1111/j.1572-0241.2002.07057.x 9093625
24. S Sherlock J Dooley, Diseases of the liver and biliary system Blackwell Science Ltd Tenth 1997 531 546
25. European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. G Fattovich M Pantalena I Zagni G Realdi SW Schalm E Christensen, Am J Gastroenterol 2002 97 2886 2895 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.0.CO;2-6 12425564
26. Analysis of factors affecting the Appearance of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C: A long term follow up study after Histologic Diagnosis. Y Aizawa Y Shibamoto I Takagi M Zeniya G Toda, Cancer 2000 89 53 58 10.1016/0140-6736(90)90474-J 10897000
27. Hepatitis C antibodies in Southern African blacks with hepatocellular carcinoma. MC Kew M Houghton QL Choo G Kuo, Lancet 1990 335 873 874 10.1016/S0140-6736(09)60207-5 1691422
28. Hepatitis B virus infection. YF Liaw CM Chu, Lancet 2009 373 582 592 10.1016/j.jhep.2008.01.023 19217993
29. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. G Raimondo G Navarra S Mondello L Costantino G Colloredo E Cucinotta G Di Vita C Scisca G Squadrito T Pollicino, J Hepatol 2008 48 743 746 10.1002/(SICI)1097-0142(19960601)77:11<2223::AID-CNCR7>3.0.CO;2-Q 18314221
30. Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. F Trevisani PE D'Intino GL Grazi P Caraceni A Gasbarrini A Colantoni GF Stefanini A Mazziotti G Gozzetti G Gasbarrini M Bernardi, Cancer 1996 77 2223 2232 10.1111/j.1365-3148.1993.tb00099.x 8635088
31. Viral hepatitis. AJ Zuckerman, Transfus Med 1993 3 7 19 8038899
32. Chronic hepatitis B virus infection: treatment strategies for the next millennium. H Arshard H Malike L William, Ann Intern Med 2000 132 723 731 10.1016/S0035-9203(97)90029-8 10787366
33. Hepatitis C virus and HIV antibodies in patients with hepatocellular carcinoma in Zimbabwe: a pilot study. M Weining JG Harkim I Gudza O Tobaiwa, Trans Roy Soc Trop Med and Hyg 1997 91 570 572 10.1002/hep.21321
34. Hepatitis C virus entry: molecular biology and clinical implications. H Barth TJ Liang TF Baumert, Hepato 2006 44 527 535 10.1002/(SICI)1097- 0142(19981015)83:8+<1723::AID-CNCR13>3.0.CO;2-W
35. Hepatocellular carcinoma in Asian Americans. HW Hann, Cancer 1998 83 1723 1727 10.1053/bega.1999.0072
36. HCV genotypes: role in pathogenesis of disease and response to therapy. G Webster E Barnes D Brown G Dusheiko, Baillieres Best Pract Res Clin Gastroenterol 2000 14 229 240 10890318
37. MM Chirara, Epidemiology of the Hepatitis B virus and the determination of the surface antigen gene nucleotide sequence. A. PhD thesis University of Zimbabwe 1993
38. K Okada H Okada, Primary Liver cell carcinoma Oxford Textbook of Clinical Hepatology, Neil Mcinyre, 1997 2 1019 1052
39. Human exposure to aflatoxins in Zimbabwe. CB Nyathi CF Mutiro JA Hasler CJ Chetsanga, Cent Afr J Med 1989 35 542 545 2485709